WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL

• Katherine Tuttle,
• Sibylle Hauske,
• Shimoli V. Shah,
• Lisa Cronin,
• Zhichao Sun,
• Dick de Zeeuw,
• Hiddo J.L. Heerspink,
• Peter Rossing

Affiliations

Katherine Tuttle

Spokane, Nephrology Division, Department of Medicine, United States

Sibylle Hauske

CMR Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Vth Department of Medicine, University Medical Center Mannheim, Heidelberg University

Shimoli V. Shah

Global Patient Safety & Pharmacovigilance, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield

Lisa Cronin

CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield

Zhichao Sun

Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield

Dick de Zeeuw

Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen

Hiddo J.L. Heerspink

Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen

Peter Rossing

Complications Research, Steno Diabetes Center Copenhagen, Copenhagen,